Adult
Baloxavir
Warning
General Information
Cap-dependent endonuclease inhibitor
Restricted formulary antimicrobial: For details see OUH netFormulary Note formulary age restriction of 12 years – 64 years.
For all information regarding contra-indications, interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).
Standard dose
|
Patient body weight |
Oral baloxavir marboxil dose |
|
80kg or more |
80mg po single dose |
|
20kg upto 80kg |
40mg po single dose |
Renal and hepatic impairment
Renal impairment
- No dose adjustment required.
Hepatic impairment
- Mild or moderate hepatic impairment (Child-Pugh class A or B): No dose adjustment is required.
- Severe hepatic impairment (Child-Pugh class C): Safety and efficacy have not been established in this patient group.
References
- UKHSA (2026) Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. Accessed 26/10/26. LINK
- Roche Products Limited. Xofluza 40 mg film coated tablets summary of product characteristics. Electronic medicines compendium. Last revision of the text 29/12/25. Accessed via www.medicines.org.uk Accessed 26/10/26.
- British National Formulary. Baloxavir marboxil. BNF online accessed via www.medicinescomplete.com Accessed 26/10/26.
- The Renal Drug Database. Baloxavir marboxil. Last updated 31/10/23. Accessed via https://renaldrugdatabase.com Accessed 26/10/26.